Quarterly anti-VEGF dosing for AMD improves vision in some patients

HONOLULU — A subset of patients receiving anti-VEGF treatment for neovascular age-related macular degeneration respond to treatment with less-than-monthly dosing, according to a poster presented here at the Association for Research in Vision and Ophthalmology meeting.
David A. Eichenbaum, MD, and colleagues compiled data from a group of studies that looked at dosing frequency of Lucentis (ranibizumab, Genentech) or Eylea (aflibercept, Regeneron) for these patients and concluded that half of them maintained or gained vision when dosed every 12 weeks (quarterly).
Studies included PIER,

Full Story →